by Pete Celano | Nov 4, 2025 | Uncategorized
From Baltimore, Maryland-based Healthworx (Healthworx operates at the intersection of healthcare and innovation by creating, co-creating and investing in companies that are improving healthcare quality, accessibility and affordability. As the innovation and investment...
by Pete Celano | Nov 3, 2025 | Uncategorized
Here’s a summary of the 10/25/2025 article “Systematic Mapping of Worldwide Research on Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‑Associated Steatohepatitis (MASH)” (PMID: 41137873) on global research trends...
by Pete Celano | Oct 29, 2025 | Uncategorized
This past year, the august Global Think-tank on Steatotic Liver Disease developed the People-First Liver Charter (https://lnkd.in/gkbxQfc9) with a powerful shared vision: a universal approach that places people living with liver conditions at the very center of care,...
by Pete Celano | Oct 26, 2025 | Uncategorized
“Conclusion: In patients with MASH who achieve a ≥10% weight loss, GLP-1RAs and dual agonists are associated with significant improvements in hepatic fibrosis, whereas their effect is limited in those with <10% weight loss. However, a significant reduction in...
by Pete Celano | Oct 22, 2025 | Uncategorized
Fascinating article regarding patients in China, titled “The nomenclature of fatty liver disease and its impact on obesity traits, insulin resistance, and hepatic fibrosis” (Xiang L. et al., Lipids in Health and Disease, 2025), is summarized here. ✅ Study Purpose The...
